Pasithea Therapeutics Valuation
| KTTA Stock | USD 1.25 0.01 0.81% |
Today, the company appears to be overvalued. Pasithea Therapeutics holds a recent Real Value of $1.2 per share. The prevailing price of the company is $1.25. Our model determines the value of Pasithea Therapeutics from analyzing the company fundamentals such as Shares Owned By Institutions of 6.09 %, shares outstanding of 1.27 M, and Return On Equity of -0.68 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pasithea Therapeutics' valuation include:
Price Book 0.0889 | Enterprise Value | Enterprise Value Ebitda 2.9009 | Price Sales 42.1513 | Enterprise Value Revenue 277.4414 |
Overvalued
Today
Please note that Pasithea Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Pasithea Therapeutics is based on 3 months time horizon. Increasing Pasithea Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pasithea Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pasithea Stock. However, Pasithea Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.25 | Real 1.2 | Target 2.0 | Hype 1.25 |
The real value of Pasithea Stock, also known as its intrinsic value, is the underlying worth of Pasithea Therapeutics Company, which is reflected in its stock price. It is based on Pasithea Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pasithea Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pasithea Therapeutics Corp helps investors to forecast how Pasithea stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pasithea Therapeutics more accurately as focusing exclusively on Pasithea Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pasithea Therapeutics' intrinsic value based on its ongoing forecasts of Pasithea Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pasithea Therapeutics' closest peers. If more than one evaluation category is relevant for Pasithea Therapeutics we suggest using both methods to arrive at a better estimate.
Pasithea Therapeutics Cash |
|
Pasithea Valuation Trend
Comparing Pasithea Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Pasithea Therapeutics Corp uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Pasithea Therapeutics Total Value Analysis
Pasithea Therapeutics Corp is now anticipated to have valuation of (10.39 M) with market capitalization of 1.58 M, debt of 81.68 K, and cash on hands of 47.94 M. The negative valuation of Pasithea Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Pasithea Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(10.39 M) | 1.58 M | 81.68 K | 47.94 M |
Pasithea Therapeutics Investor Information
About 19.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.09. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pasithea Therapeutics recorded a loss per share of 14.79. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 2nd of January 2024. Based on the key indicators related to Pasithea Therapeutics' liquidity, profitability, solvency, and operating efficiency, Pasithea Therapeutics Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Pasithea Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pasithea Therapeutics has an asset utilization ratio of 1.86 percent. This suggests that the Company is making $0.0186 for each dollar of assets. An increasing asset utilization means that Pasithea Therapeutics Corp is more efficient with each dollar of assets it utilizes for everyday operations.Pasithea Therapeutics Ownership Allocation
Pasithea Therapeutics holds 19.08 pct. of its outstanding shares held by insiders and 6.09 pct. owned by third-party entities.Pasithea Therapeutics Profitability Analysis
The company reported the previous year's revenue of 486.56 K. Net Loss for the year was (15.51 M) with loss before overhead, payroll, taxes, and interest of (2.21 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Pasithea Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Pasithea Therapeutics and how it compares across the competition.
About Pasithea Therapeutics Valuation
The stock valuation mechanism determines Pasithea Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Pasithea Therapeutics. We calculate exposure to Pasithea Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pasithea Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -583.6 K | -554.4 K | |
| Pretax Profit Margin | (25.78) | (27.07) | |
| Operating Profit Margin | (27.41) | (28.78) | |
| Net Loss | (24.15) | (25.36) | |
| Gross Profit Margin | 0.69 | 0.73 |
Pasithea Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.2 M |
Pasithea Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Pasithea Therapeutics Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Pasithea we look at many different elements of the entity such as Pasithea's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pasithea Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pasithea Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pasithea Therapeutics' worth.Complementary Tools for Pasithea Stock analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |